(S041) Intensity-Modulated Involved-Site Radiation Therapy for Non-Hodgkin Lymphoma of the Head and Neck

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

Outcomes for head and neck NHL were maintained using ISRT with IMRT, with no marginal failures. ISRT reduces dose to normal tissues, and our results suggest that further reductions can be achieved with IMRT. This approach may be most valuable for definitive treatment of early-stage NHL, as the excellent prognosis highlights the importance of minimizing RT sequelae.

Zachary D. Guss, MD, MSc, Abdossalam M. Madkhali, MBBS, MSc, Yin Zhang, PhD, Samson Dah, BS, Joseph Moore, PhD, Stephanie A. Terezakis, MD; Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University; Oxford Institute for Radiation Oncology, University of Oxford; Department of Medicine, King Saud University

PURPOSE/OBJECTIVES: Involved-field radiation therapy (IFRT) for non-Hodgkin lymphoma (NHL) of the head and neck has historically been delivered using conventional techniques. Modern techniques, such as intensity-modulated radiation therapy (IMRT) and involved-site radiation therapy (ISRT), may spare normal tissues and maintain excellent clinical outcomes.

MATERIALS AND METHODS: A retrospective study was conducted of patients aged > 18 years at diagnosis of NHL and involvement of the head and neck treated with ISRT using IMRT. Patients were evaluated for local control, overall survival (OS), and radiation-related toxicities. Conventional ISRT (c-ISRT) and IFRT (c-IFRT) treatment plans were also generated. A paired t-test was used to evaluate whether the RT approach resulted in differences in dose to organs at risk. Excess absolute risk (EAR) of secondary malignancy due to RT was calculated using the linear no-threshold model and parameters derived from the organ equivalent dose concept and Biological Effects of Ionizing Radiation VII report.

RESULTS: A total of 21 patients with a median age of 61 years (range: 32–85 yr) and a median follow-up of 31 months (range: 2–55 mo) were evaluated. Fifteen (71%) patients had early-stage (I/II) NHL, and six (29%) had advanced-stage NHL. OS for early-stage patients was 100%. Two patients failed locally, both in-field in the context of aggressive advanced-stage disease. Toxicities were mild. Dmax to the spinal cord and brainstem was the lowest using IMRT (P < .05). EAR for early-stage patients per 10,000 person-years for IMRT was 11.7, lower than that of c-ISRT (15.3; P = .02) and c-IFRT (12.8; P = .04).

CONCLUSION: Outcomes for head and neck NHL were maintained using ISRT with IMRT, with no marginal failures. ISRT reduces dose to normal tissues, and our results suggest that further reductions can be achieved with IMRT. This approach may be most valuable for definitive treatment of early-stage NHL, as the excellent prognosis highlights the importance of minimizing RT sequelae.

Proceedings of the 98th Annual Meeting of the American Radium Society -americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Related Content